Treatment of chronic hepatitis C in patients who have failed to respond to IFN or IFN and ribavirin combination therapy
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Approximately 45% of patients with chronic hepatitis C infection fail to achieve a sustained virologic response when treated with pegylated interferon (IFN) and ribavirin combination therapy. The lack of early virologic response after 12 to 24 weeks of therapy can be a reliable indicator of those who will not benefit from continuing the treatment for 48 weeks. The presence of genotype 1, high viral load, and advanced fibrosis are among the factors that can predict those patients who have higher rates of nonresponse. Nonresponders to IFN monotherapy and IFN plus ribavirin combination therapy can benefit from retreatment with pegylated IFN and ribavirin combination therapy. Treatment options for nonresponders to pegylated IFN and ribavirin are being investigated in several trials. The role of maintenance pegylated IFN is also under investigation, although preliminary evidence suggests that some patients may derive benefit.
- McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998, 339:1485–1492. CrossRef
- Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965. Shows that peginterferon in combination with ribavirin is the most effective therapy for HCV. CrossRef
- Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982. Peginterferon alfa-2a and ribavirin lead to overall SVR of 56%. CrossRef
- Di Bisceglie AM, Conjeevaram HS, Fried MW, et al.: Ribavirin as therapy for chronic hepatitis C. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med 1995, 123:897–903.
- Pawlotsky JM, Bouvier-Alias M, Hezode C, et al.: Standardization of hepatitis C virus RNA quantification. Hepatology 2000, 32:654–659. CrossRef
- Management of hepatitis C [no authors listed]. NIH Consens Statement 1997, 15:1–41.
- Lau DT, Kleiner DE, Ghany MG, et al.: 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998, 28:1121–1127. CrossRef
- Marcellin P, Boyer N, Gervais A, et al.: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997, 127:875–881.
- Heathcote EJ, Shiffman ML, Cooksley WG, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673–1680. CrossRef
- Zeuzem S, Feinman SV, Rasenack J, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666–1672. CrossRef
- Lindsay KL, Trepo C, Heintges T, et al.: A randomized, doubleblind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001, 34:395–403. CrossRef
- McHutchison JG, Shad JA, Gordon SC, et al.: Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat 2001, 8:414–420. CrossRef
- Davis GL: Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002, 136:S145-S151. CrossRef
- Bassett SE, Di Bisceglie AM, Bacon BR, et al.: Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Hepatology 1999, 29:1884–1892. CrossRef
- Beinker NK, Voigt MD, Arendse M, et al.: Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 1996, 25:633–638. CrossRef
- Giannini E, Mastracci L, Botta F, et al.: Liver iron accumulation in chronic hepatitis C patients without HFE mutations: relationships with histological damage, viral load and genotype and [Alpha;]-glutathione S-transferase levels. Eur J Gastroenterol Hepatol 2001, 13:1355–1361. CrossRef
- Hezode C, Cazeneuve C, Coue O, et al.: Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999, 31:979–984. CrossRef
- Kageyama F, Kobayashi Y, Murohisa G, et al.: Failure to respond to interferon-alpha 2a therapy is associated with increased hepatic iron levels in patients with chronic hepatitis C. Biol Trace Elem Res 1998, 64:185–196.
- Guyader D, Boucher E, Andre P, et al.: A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon. Am J Gastroenterol 1999, 94:1696–1698. CrossRef
- Tsai NC, Zuckerman E, Han SH, et al.: Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997, 92:1831–1834.
- Van Thiel DH, Friedlander L, Molloy PJ, et al.: Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepatogastroenterology 1996, 43:1557–1561.
- Di Bisceglie AM, Bonkovsky HL, Chopra S, et al.: Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000, 32:135–138. CrossRef
- Reddy KR, Hoofnagle JH, Tong MJ, et al.: Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999, 30:787–793. CrossRef
- Howell C, Jeffers L, Hoofnagle JH: Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000, 119:1385–1396. This is an important summary of the National Institutes of Health workshop on hepatitis C in African Americans. CrossRef
- Muir AJ, Bornstein JD, Killenberg PG, et al.: Pegylated interferon alfa-2b and ribavirin for the treatment of chronic hepatitis C infection in African Americans and non-Hispanic whites. A preliminary report [abstract]. Gastroenterology 2002, 122:116. CrossRef
- Gish RG: Standards of treatment in chronic hepatitis C. Semin Liver Dis 1999, 19:35–47.
- Alberti A, Chemello L, Noventa F, et al.: Therapy of hepatitis C: retreatment with alpha interferon. Hepatology 1997, 26:137S-142S. CrossRef
- Heathcote EJ, Keeffe EB, Lee SS, et al.: Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998, 27:1136–1143. CrossRef
- Minuk GY, Reddy KR, Lee SS, et al.: Enhanced virologic response to treatment with 40KDA peginterferon-alpha-2a (Pegasys) in patients previously unresponsive to treatment with interferon-alpha-2a. Hepatology 2001, 34:330A. This preliminary report shows that peginterferon is effective in nonresponders to IFN. CrossRef
- Chow WC, Boyer N, Pouteau M, et al.: Re-treatment with interferon alfa of patients with chronic hepatitis C. Hepatology 1998, 27:1144–1148. CrossRef
- Heathcote EJ, James S, Mullen KD, et al.: Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group. Hepatology 1999, 30:562–566. CrossRef
- Shiffman ML, Hofmann CM, Gabbay J, et al.: Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group. Am J Gastroenterol 2000, 95:2928–2935. CrossRef
- Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, et al.: Combination of interferon and ribavirin in chronic hepatitis C: retreatment of nonresponders to interferon. Hepatology 2001, 33:704–707. CrossRef
- Barbaro G, Di Lorenzo G, Soldini M, et al.: Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study. Am J Gastroenterol 1998, 93:2445–2451.
- Jacobson IM, Russo MW, Brown RS, et al.: Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in previous non-responders to interferon monotherapy or combination therapy and in combination therapy relapsers [abstract]. Gastroenterology 2002, 122:79. The preliminary results of this trial show that peginterferon alfa-2b plus ribavirin combination therapy is effective for nonresponders.
- Shiffman ML, et al., for the HALT-C investigators: Retreatment of interferon and interferon-ribavirin non-responders with peginterferon-alpha-2a and ribavirin: Initial results from the lead-in-phase of the HALT-C trial. Hepatology 2001, 34:243A. The preliminary results of this trial also show that peginterferon alfa-2a plus ribavirin can lead to sustained responses in nonresponders. CrossRef
- Schiff ER, de Medina M, Kahn RS: New perspectives in the diagnosis of hepatitis C. Semin Liver Dis 1999, 19(suppl):3–16.
- Gerotto M, Sullivan DG, Polyak SJ, et al.: Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. J Virol 1999, 73:7241–7247.
- Chemello L, Cavalletto L, Donada C, et al.: Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997, 113:1654–1659. CrossRef
- Shiffman ML, Hofmann CM, Contos MJ, et al.: A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999, 117:1164–1172. CrossRef
- Smith JP: Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997, 42:1681–1687. CrossRef
- Younossi ZM, Perrillo RP: The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Semin Liver Dis 1999, 19:95–102.
- Treatment of chronic hepatitis C in patients who have failed to respond to IFN or IFN and ribavirin combination therapy
Current Hepatitis Reports
Volume 2, Issue 1 , pp 32-39
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links